

Clenbuterol

A long-acting phenylaminoethanol beta-2 adrenoceptor agonist developed at Boehringer Ingelheim as a bronchodilator, distinguished from other sympathomimetic beta-agonists by exceptional oral bioavailability, a prolonged elimination half-life of 25 to 39 hours, and potent repartitioning activity on skeletal muscle and adipose tissue that has driven extensive preclinical and clinical investigation in muscle-wasting disorders, body composition, and neuromuscular disease.

DOCUMENT	KDC-MN-1533
ISSUED	2026-05-15
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Selective beta-2 adrenergic receptor agonist with anabolic, lipolytic, and bronchodilatory activity

ABSTRACT

Clenbuterol (4-amino- α -[[[1,1-dimethylethyl)amino]methyl]-3,5-dichlorobenzyl alcohol; NAB 365) is a selective, long-acting beta-2 adrenergic receptor agonist originally synthesized in 1967 at the Thomae research facility of Boehringer Ingelheim in Biberach, Germany, and approved in 1976 in that country for the treatment of reversible airway obstruction in asthma and chronic obstructive pulmonary disease. The compound acts through stimulation of the beta-2 adrenoceptor, a seven-transmembrane G-protein-coupled receptor that activates adenylyl cyclase, elevates intracellular cyclic adenosine monophosphate, and engages protein kinase A signaling cascades in airway smooth muscle, skeletal muscle, adipose tissue, and hepatocytes. In airway smooth muscle the principal consequence is bronchodilation; in skeletal muscle and adipose tissue the consequences are protein accretion and lipolysis, respectively, producing a body-composition repartitioning effect that has generated an extensive preclinical and applied research literature spanning livestock science, sports pharmacology, and clinical investigation in muscle-wasting disease.

Pharmacokinetics in humans are characterized by rapid oral absorption (bioavailability approximately 70 to 80 percent), minimal hepatic first-pass metabolism, a prolonged terminal elimination half-life of 25 to 39 hours (substantially longer than the structurally related short-acting beta-2 agonists salbutamol and terbutaline), and predominant renal excretion of unchanged drug. The extended half-life supports once- or twice-daily oral

dosing and produces measurable plasma accumulation on chronic administration, reaching steady state in approximately 4 days. Five minor metabolites have been identified in human and animal studies, none with significant pharmacological activity at the beta-2 receptor.

The compound is approved for human bronchospastic indications in multiple European and Latin American jurisdictions but has never received approval from the United States Food and Drug Administration for human use. In the United States, clenbuterol hydrochloride is approved solely for veterinary use as Ventipulmin Syrup (Boehringer Ingelheim Vetmedica) for the management of airway obstruction in horses, under a New Animal Drug Application approved by the FDA in 1998. The compound is classified as a prohibited substance under the World Anti-Doping Agency Prohibited List (category S1.2, other anabolic agents) and is banned in competition and out-of-competition in all sports under the WADA Code. Its use as a growth-promoting agent in food-producing animals is prohibited in the European Union, the United States, and China, though enforcement challenges have produced recurring food-safety incidents.

Beyond the registered bronchodilator indication, the principal research applications of clenbuterol are in neuromuscular disease, where pilot and open-label clinical trials have demonstrated safety and preliminary efficacy signals in spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, and spinal muscular atrophy; in skeletal muscle physiology, where the compound is the reference beta-2 agonist for studying adrenergic regulation of protein synthesis, proteolysis, and fiber-type transitions; and in cardiac biology, where the compound has been studied as a bridge-to-recovery adjunct in patients with heart failure

supported by left ventricular assist devices. The cardiac research application is notable given the concurrent identification of dose-dependent myocardial toxicity in animal models and in clinical case reports of supratherapeutic use, producing a narrow therapeutic index for cardiac applications that remains an active area of investigation.

This monograph reviews the chemistry, synthesis, and stereochemistry of clenbuterol; the receptor pharmacology and downstream signaling; the comprehensive human pharmacokinetic record; preclinical pharmacology across muscle, adipose, and cardiac tissue; the clinical evidence base across bronchospastic, neuromuscular, cardiac, and body-composition indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications; adverse-event signal including cardiac toxicity; and a structured comparative assessment of five alternative beta-2 adrenergic agonists against clenbuterol on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Clenbuterol.

Marketed names: Spiropent (Boehringer Ingelheim; Germany, several European Union member states, Latin America), Ventipulmin (Boehringer Ingelheim Vetmedica; United States, veterinary use only), Broncodil (generic markets), Novegam (generic), Oxyflux (generic, Mexico and Latin America), Prontovent (generic), Dilaterol (United Kingdom, veterinary).

Development codes: NAB 365 (Thomae/Boehringer Ingelheim). The development code appears in the early pharmacology literature, including the dose-response characterization by Engelhardt (1976) and the initial bronchodilator clinical trials in Germany [1].

Chemical Abstracts Service registry numbers: 37148-27-9 (free base), 21898-19-1 (hydrochloride salt). The hydrochloride salt is the pharmaceutical form used in all marketed preparations and in the majority of research-grade supply.

International Union of Pure and Applied Chemistry name: 1-(4-amino-3,5-dichlorophenyl)-2-[(1,1-dimethylethyl)amino]ethanol. The compound is a substituted phenylaminoethanol bearing two chlorine atoms at the 3 and 5 positions of the aromatic ring, an amino group at the 4-position, and a tert-butylamino group on the ethanolamine side chain.

PubChem CID: 2783 (free base); 5702273 (hydrochloride).

DrugBank ID: DB01407.

1.2 Structural class and chemistry

Clenbuterol is a phenylethanolamine sympathomimetic amine structurally related to salbutamol (albuterol), terbutaline, fenoterol, and other beta-2 adrenergic receptor agonists used in the management of bronchospasm. It is distinguished within the beta-2 agonist class by the presence of two aromatic chlorine substituents (3,5-

dichloro) and a 4-amino group on the phenyl ring, producing a halogenated aniline pharmacophore that confers metabolic stability and a substantially longer elimination half-life than the hydroxylated-ring analogs (salbutamol, terbutaline) [2].

Molecular formula: C₁₂H₁₈Cl₂N₂O (free base); C₁₂H₁₉Cl₃N₂O (hydrochloride).

Exact mass: 276.0796 g/mol (free base, monoisotopic).

Molecular weight: 277.19 g/mol (free base); 313.65 g/mol (hydrochloride salt).

Physical properties: White to off-white crystalline powder. The hydrochloride salt is freely soluble in water, methanol, and ethanol; sparingly soluble in acetone; practically insoluble in diethyl ether and nonpolar organic solvents. Melting point of the hydrochloride salt is approximately 174 to 175.5 degrees Celsius. The compound is stable under normal storage conditions and is not light-sensitive under standard pharmaceutical storage.

Stereochemistry: Clenbuterol contains one stereocenter at the beta-carbon of the ethanolamine side chain and exists as two enantiomers: the (R)-(-) and (S)-(+) forms. The marketed pharmaceutical preparations and the majority of research-grade supply are provided as the racemic mixture. The (R)-enantiomer is the eutomer (the more pharmacologically active enantiomer) at the beta-2 adrenergic receptor, with approximately 100-fold greater binding affinity than the (S)-enantiomer, consistent with the stereoselectivity pattern observed across the phenylethanolamine beta-agonist class [3]. Investigators conducting mechanism-of-action studies should note that the racemic material delivers half the active enantiomer on a weight basis and that enantioselective assays are required for precise pharmacokinetic characterization.

1.3 Synthesis

The published synthesis of clenbuterol proceeds through standard phenylaminoethanol chemistry. The principal route involves: (a) preparation of 4-amino-3,5-dichloroacetophenone from 4-aminoacetophenone by selective ring chlorination at positions 3 and 5 using sulfuryl chloride or N-chlorosuccinimide; (b) alpha-bromination of the methyl ketone to the alpha-bromoketone using bromine or N-bromosuccinimide; (c) nucleophilic displacement of the alpha-bromine by tert-butylamine in refluxing toluene or isopropanol; and (d) sodium borohydride reduction of the resulting alpha-(tert-butylamino)ketone to the racemic 1-(4-amino-3,5-dichlorophenyl)-2-(tert-butylamino)ethanol [4]. The hydrochloride salt is formed by

treatment with hydrogen chloride in isopropanol or diethyl ether and is recrystallized to pharmaceutical purity. Industrial syntheses report overall yields in the range of 45 to 65 percent from the starting acetophenone. Alternative synthetic routes employing reductive amination of the dichloroaminophenacyl alcohol with tert-butylamine have been described. Resolution of the racemate to individual enantiomers has been accomplished by chiral chromatography and by diastereomeric salt formation with chiral acids, but is not routinely performed for commercial supply. The original Boehringer Ingelheim synthesis was patented in the United States in 1970 (US Patent 3,536,712) [5].

2. Abstract

Clenbuterol (NAB 365) is a selective, long-acting beta-2 adrenergic receptor agonist that produces bronchodilation through relaxation of airway smooth muscle and exerts potent anabolic and lipolytic repartitioning effects on skeletal muscle and adipose tissue through the same receptor system [1, 2]. The compound was synthesized in 1967, patented in 1970, and approved in Germany in 1976 for bronchospastic airway disease. It has not been approved by the United States Food and Drug Administration for human use.

The pharmacological profile of clenbuterol is defined by three characteristics that distinguish it from other beta-2 agonists in the class. First, the 3,5-dichloro-4-amino substitution pattern on the phenyl ring confers resistance to catechol-O-methyltransferase and monoamine oxidase metabolism, producing an elimination half-life of 25 to 39 hours in humans, approximately 5- to 10-fold longer than salbutamol (4 to 6 hours) and terbutaline (3 to 4 hours) [6, 7]. Second, the compound produces a pronounced skeletal muscle anabolic effect at doses that overlap with or modestly exceed the bronchodilator dose range, with preclinical evidence demonstrating 19 to 39 percent increases in skeletal muscle mass in rats across all age groups and fiber-type-specific hypertrophy favoring fast-twitch (type II) fibers [8, 9]. Third, the compound produces dose-dependent lipolysis through beta-2-mediated activation of hormone-sensitive lipase in adipocytes, with measurable increases in energy expenditure and fat oxidation demonstrated in both animal and human studies [10].

The clinical evidence base spans multiple domains. The registered indication is reversible airway obstruction (asthma, chronic obstructive pulmonary disease), where clenbuterol at 20 to 40 micrograms twice daily produces bronchodilation comparable to salbutamol at 200 micrograms four times daily [1]. In neuromuscular disease, pilot clinical trials have evaluated clenbuterol in spinal and bulbar muscular atrophy (SBMA), where a 12-month open-label trial of 40 micrograms daily demonstrated improved motor function [11]; in amyotrophic lateral sclerosis (ALS), where an open-label trial demonstrated slowed functional decline [12]; and in spinal muscular atrophy (SMA), where preclinical evidence supports upregulation of survival motor neuron 2 (SMN2) gene expression through beta-adrenergic signal-

ing [13]. In cardiac surgery, clenbuterol has been investigated as a pharmacological adjunct to left ventricular assist device (LVAD) support, producing evidence of reverse myocardial remodeling in a series of studies from the Harefield group [14].

The principal safety concern with clenbuterol is dose-dependent cardiovascular toxicity. At supratherapeutic doses (those used in performance-enhancement and body-composition contexts, typically 60 to 200 micrograms daily or higher), the compound produces tachycardia, hypokalemia, QT prolongation, myocardial ischemia, and, in severe cases, myocardial necrosis [15, 16, 17]. Animal studies have demonstrated subendocardial necrosis in the left ventricle following clenbuterol administration at anabolic-range doses, an effect attenuated by beta-blocker pretreatment [18]. Case reports of hospitalization and cardiac arrest following supratherapeutic clenbuterol use are present in the clinical toxicology literature, and no minimum toxic dose has been established with confidence [17]. The therapeutic index for anabolic and body-composition applications is therefore narrow and not well characterized in controlled human studies.

This monograph documents the chemistry, synthesis, stereochemistry, receptor pharmacology, signaling pathways, pharmacokinetics, preclinical pharmacology, clinical evidence across all studied indications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event profile including cardiac toxicity, and a structured comparative assessment of five alternative beta-2 adrenergic agonists (salbutamol, formoterol, salmeterol, terbutaline, and BRL-47672) against clenbuterol on five standards: novelty, effect size, promising potential, side-effect profile, and overall validation.

3. Discovery and Development History

3.1 Origin

Clenbuterol (NAB 365) was synthesized in 1967 at the Karl Thomae GmbH research facility (a subsidiary of Boehringer Ingelheim) in Biberach an der Riss, Germany. The compound emerged from a systematic structure-activity exploration of substituted phenylaminoethanols designed to maximize selectivity for the beta-2 adrenoceptor subtype in bronchial smooth muscle while minimizing activation of the beta-1 adrenoceptor in cardiac tissue [1]. The design strategy introduced halogen substituents at the 3 and 5 positions of the phenylaminoethanol scaffold to increase metabolic stability and duration of action while preserving high beta-2 receptor affinity. The 4-amino group was incorporated for additional metabolic resistance and receptor-binding optimization. The resulting compound, designated NAB 365, demonstrated high beta-2 selectivity (beta-2/beta-1 ratio approximately 4:1 in functional assays) and an extended duration of bronchodilator action that was unprecedented in the phenylethanolamine class at the time of its characterization [2].

3.2 Bronchodilator registration

The synthesis of clenbuterol hydrochloride was patented in the United States in 1970. Following preclinical pharmacology, toxicology, and Phase 1 healthy-volunteer pharmacokinetic studies, the compound was approved for human use in the Federal Republic of Germany in 1976 for the treatment of reversible airway obstruction in asthma and chronic obstructive pulmonary disease at an oral dose of 20 micrograms twice daily [1, 5]. Subsequent registrations followed in Austria, Italy, Spain, Portugal, Belgium, several Eastern European countries, multiple Latin American jurisdictions (Mexico, Brazil, Argentina), and selected East Asian markets. The compound was marketed by Boehringer Ingelheim as Spiropent in most European markets. The registered oral dose range is 20 to 40 micrograms twice daily in adults and 10 to 20 micrograms twice daily in children. Inhalational formulations were also developed but were less commercially successful than the oral preparation. The compound was not submitted for registration in the United States or the United Kingdom; the short-acting beta-2 agonist salbutamol (approved 1969

in the UK, 1981 in the US) had achieved dominant market position in those jurisdictions, and the regulatory pathway for a second-line bronchodilator with a narrower therapeutic index was not commercially pursued.

3.3 Veterinary registration

In the United States, Boehringer Ingelheim Vetmedica obtained FDA approval for clenbuterol hydrochloride as Ventipulmin Syrup (72.5 micrograms per milliliter) under New Animal Drug Application (NADA) 140-973 in 1998, for the management of airway obstruction in horses associated with respiratory disease [19]. The veterinary indication remains the sole FDA-approved use of clenbuterol in the United States. Clenbuterol was also approved for veterinary use in Germany in 1980 for the treatment of bronchiolytic disorders in horses and cattle. The compound is not approved for use in food-producing animals in the United States, the European Union, or China.

3.4 Identification of anabolic properties

The anabolic and repartitioning properties of clenbuterol were first systematically characterized in the early 1980s when livestock-science researchers demonstrated that chronic oral administration of clenbuterol to cattle, sheep, pigs, and poultry produced substantial increases in skeletal muscle mass and decreases in carcass fat [8, 20]. The Ricks et al. (1984) study established that clenbuterol in feed produced 15 to 30 percent increases in skeletal muscle mass with concomitant 15 to 25 percent decreases in carcass fat in cattle. The Reeds et al. (1986) study characterized the mechanism as involving decreased protein degradation rather than increased protein synthesis at the whole-body level, though subsequent molecular studies revealed contributions from both processes [9, 20]. The Choo et al. (1992) study formally demonstrated that the anabolic effects were mediated through beta-2 adrenoceptor activation by showing that co-administration of the selective beta-2 antagonist ICI 118,551 abolished the muscle growth response [21]. These findings were extended to aged animals by Carter and Lynch (1994), who showed that clenbuterol reversed sarcopenic muscle loss in 23-month-old Fischer 344 rats, increasing skeletal muscle weight by 22 to 25 percent [22].

3.5 Misuse and regulatory response

The potent repartitioning effects identified in livestock studies rapidly translated to misuse in competitive sports and in food production. In livestock, the illegal administration of clenbuterol to cattle for growth promotion produced recurring food-safety incidents in Europe in the late 1980s and 1990s, including a large-scale poisoning incident in Spain in 1990 that affected over 100 individuals consuming contaminated liver [23]. These incidents led to the prohibition of beta-agonist use in food-producing animals in the European Union under Council Directive 96/22/EC. In competitive sports, the World Anti-Doping Agency classified clenbuterol as a prohibited substance under category S1.2 (other anabolic agents) on the Prohibited List, banning its use both in-competition and out-of-competition [24]. The compound has been the subject of numerous positive doping findings across athletics, cycling, boxing, and other sports, with recurring complexity around the contaminated-meat defense in athletes competing in jurisdictions where illegal livestock use persists (notably Mexico and China). WADA responded in 2019 by introducing a minimum reporting threshold of 5 ng/mL for clenbuterol in urine, below which findings from athletes recently visiting known-contamination countries may be reported as atypical rather than adverse analytical findings.

3.6 Expansion to neuromuscular and cardiac indications

Beginning in the early 2000s, the demonstrated anabolic activity on skeletal muscle drove clinical investigation of clenbuterol in neuromuscular disease. The rationale was that beta-2 agonist-mediated protein accretion could offset the progressive muscle wasting characteristic of motor neuron diseases and muscular dystrophies. Pilot clinical trials in spinal and bulbar muscular atrophy (Querin et al. 2013), amyotrophic lateral sclerosis (Meijer et al. 2023), and spinal muscular atrophy preclinical models have been reported [11, 12, 13]. In parallel, the Harefield Hospital group in London investigated clenbuterol as a pharmacological adjunct to left ventricular assist device support for end-stage heart failure, demonstrating myocardial reverse remodeling in a small cohort [14].

4. Mechanism of Action

Clenbuterol exerts its pharmacological effects primarily through agonism at the beta-2 adrenergic receptor (beta-2 AR, ADRB2), a class A G-protein-coupled receptor expressed on airway smooth muscle, skeletal muscle fibers, adipocytes, hepatocytes, uterine smooth muscle, vascular smooth muscle, cardiac myocytes, and multiple immune cell populations. The compound also possesses low-level agonist activity at the beta-1 adrenergic receptor and negligible activity at alpha-adrenergic receptors at therapeutic concentrations.

4.1 Beta-2 adrenergic receptor agonism and downstream signaling

The beta-2 adrenergic receptor is coupled to the stimulatory G-protein (Gs). Upon agonist binding, the receptor undergoes a conformational change that activates the Gs alpha subunit, which in turn stimulates the membrane-bound enzyme adenylyl cyclase. Adenylyl cyclase catalyzes the conversion of adenosine triphosphate to 3',5'-cyclic adenosine monophosphate (cAMP), elevating intracellular cAMP concentration. Elevated cAMP activates protein kinase A (PKA), which phosphorylates multiple downstream effectors depending on the cell type [2, 10].

In airway smooth muscle, PKA phosphorylation of myosin light chain kinase reduces its affinity for the calcium-calmodulin complex, producing smooth muscle relaxation and bronchodilation. PKA also phosphorylates and opens calcium-activated potassium channels, producing membrane hyperpolarization that reinforces the relaxation response. The bronchodilatory mechanism is pharmacologically identical to that of the other beta-2 agonists; the distinguishing feature of clenbuterol is the duration of receptor occupancy and the consequent prolonged bronchodilatory effect.

In skeletal muscle, clenbuterol-mediated beta-2 receptor activation produces two principal effects: increased protein synthesis through activation of the mammalian target of rapamycin (mTOR) pathway and ribosomal protein S6 kinase (S6K1) phosphorylation; and decreased protein degradation through inhibition of the ubiquitin-proteasome pathway, specifically through downregulation of the muscle-specific E3 ubiquitin ligases atrogin-1 (MAFbx) and MuRF1 [25, 26]. The Jessen et al.

(2020) study in healthy young men confirmed mTOR pathway activation (S6 phosphorylation) in human skeletal muscle biopsies following a two-week clenbuterol administration protocol [10]. Gene expression profiling by Spurlock et al. (2006) revealed additional clenbuterol-responsive pathways including regulators of transcription and translation, cell signaling mediators, and polyamine metabolism enzymes [27].

In adipose tissue, PKA phosphorylates and activates hormone-sensitive lipase (HSL) and perilipin, promoting the hydrolysis of stored triglycerides to free fatty acids and glycerol (lipolysis). The resulting free fatty acids are released into circulation for oxidative metabolism, producing the fat-loss and body-composition re-partitioning effects observed in animal and human studies [10].

4.2 Beta-2 receptor selectivity

Clenbuterol demonstrates preferential binding to the beta-2 adrenoceptor over the beta-1 adrenoceptor, with a selectivity ratio of approximately 4:1 in functional pharmacological assays using isolated tissue preparations [2, 28]. This selectivity is moderate relative to some other beta-2 agonists (formoterol selectivity ratio approximately 120:1; salmeterol approximately 50,000:1) and is a contributor to the cardiovascular side-effect profile observed at higher doses, where beta-1-mediated chronotropic and inotropic effects become clinically significant. The partial agonist character of clenbuterol at the beta-1 receptor has been characterized in isolated rat atrial preparations, where the compound produces a concentration-dependent increase in atrial rate that is approximately 20 to 30 percent of the maximal isoproterenol response [28].

4.3 Beta-2 receptor desensitization

A pharmacologically important feature of chronic clenbuterol administration is progressive desensitization of the beta-2 adrenergic receptor. The mechanism involves agonist-induced phosphorylation of the receptor by G-protein-coupled receptor kinase 2 (GRK2, also termed beta-adrenergic receptor kinase), followed by beta-arrestin recruitment, receptor internalization via clathrin-coated pits, and downregulation of cell-surface receptor density [29]. In skeletal muscle, the initial robust activation of PKA and S6K1 signaling following clenbuterol administration is substantially attenuated after approximately two weeks of continuous treatment, as demonstrated in equine studies with serial muscle biopsies [30]. In bronchial

smooth muscle, desensitization manifests clinically as tachyphylaxis to the bronchodilator effect, a phenomenon observed with chronic use of all beta-2 agonists. The desensitization kinetics vary by tissue: skeletal muscle beta-2 receptors appear to desensitize more rapidly than bronchial receptors, which has implications for the duration of anabolic efficacy in chronic dosing protocols. Recovery of receptor sensitivity requires a washout period of approximately 10 to 14 days.

4.4 Non-canonical signaling

Beyond the classical Gs-cAMP-PKA pathway, clenbuterol activates additional signaling cascades through the beta-2 receptor. The beta-arrestin-mediated pathway, initiated after receptor phosphorylation and internalization, activates extracellular signal-regulated kinases 1 and 2 (ERK1/2) through a G-protein-independent mechanism. This biased agonism may contribute to the anti-apoptotic and cytoprotective effects reported in cardiac and neuronal tissues [31]. In cardiomyocytes, the dual Gs-dependent and beta-arrestin-dependent signaling produces opposing effects on cell survival (Gs-mediated PKA overactivation can be pro-apoptotic, while beta-arrestin-mediated ERK activation is anti-apoptotic), with the net outcome depending on dose, duration, and the state of receptor desensitization. The relevance of beta-arrestin signaling to the therapeutic and toxic effects of clenbuterol in specific tissues is an area of active investigation.

4.5 Cardiac pharmacology

Clenbuterol produces both direct and indirect cardiovascular effects. The direct effects include beta-2 adrenoceptor-mediated vasodilation in skeletal muscle vasculature (reducing diastolic blood pressure and producing reflex tachycardia), and, at higher concentrations, beta-1 adrenoceptor activation producing positive chronotropy and inotropy. The compound also produces direct myocardial hypertrophy through chronic beta-adrenoceptor stimulation: sustained cAMP elevation in cardiomyocytes activates calcineurin-NFAT and other hypertrophic signaling pathways, producing pathological left ventricular hypertrophy distinct from the physiological hypertrophy of exercise [15, 18]. At pharmacological doses used in the Harefield LVAD bridge-to-recovery protocol, the hypertrophic stimulus was harnessed therapeutically to promote myocardial recovery during mechanical unloading [14]. At supratherapeutic doses in animal models, the same stimulus produces myocardial necrosis (Section 6.3).

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Clenbuterol is rapidly and extensively absorbed from the gastrointestinal tract following oral administration. Oral bioavailability is approximately 70 to 80 percent, with minimal hepatic first-pass metabolism [6, 7]. Time to peak plasma concentration is approximately 2 to 3 hours after a single oral dose. The absorption is not significantly affected by food co-administration. Inhalational administration produces rapid onset of bronchodilation within 5 to 15 minutes, with systemic absorption from the pulmonary circulation producing measurable plasma concentrations within minutes.

5.2 Distribution

Clenbuterol has a large apparent volume of distribution, reflecting extensive tissue partitioning into skeletal muscle, adipose tissue, liver, kidney, and lung. Plasma protein binding is approximately 89 to 98 percent, predominantly to albumin. The compound crosses the blood-brain barrier at low but measurable concentrations, as evidenced by the centrally mediated adverse effects (anxiety, insomnia, tremor) observed at therapeutic and supratherapeutic doses. Tissue-to-plasma ratios in animal studies are highest in the liver, lung, and kidney [6].

5.3 Metabolism

Clenbuterol undergoes minimal hepatic metabolism. The principal metabolic pathways are oxidative deamination of the tert-butylamino side chain and conjugation reactions (glucuronidation, sulfation). Five minor metabolites have been identified in human and animal urine, none with significant beta-2 agonist activity [6, 32]. The metabolic stability conferred by the 3,5-dichloro-4-amino phenyl ring (which resists catechol-O-methyltransferase, monoamine oxidase, and sulfotransferase-mediated degradation) is the principal structural basis for the long elimination half-

life. The low hepatic extraction ratio is the basis for the high oral bioavailability and for the relatively modest drug-drug interaction potential at the hepatic cytochrome P450 level.

5.4 Elimination

The terminal elimination half-life in humans is 25 to 39 hours, with most estimates centering on approximately 35 hours [6, 7]. This is substantially longer than salbutamol (4 to 6 hours), terbutaline (3 to 4 hours), and fenoterol (6 to 7 hours), and comparable to or longer than the systemic half-lives of the inhaled long-acting beta-2 agonists. Approximately 50 to 70 percent of an oral dose is excreted in urine, predominantly as unchanged drug (approximately 20 to 30 percent) and conjugated metabolites. Fecal excretion accounts for approximately 10 to 20 percent of the dose. Renal clearance is the dominant elimination pathway.

Steady-state plasma concentrations are achieved in approximately 4 days of twice-daily oral dosing, consistent with the 25- to 39-hour half-life [33]. The accumulation factor (ratio of steady-state AUC to single-dose AUC) is approximately 2 to 3 at the standard bronchodilator dosing interval. In cases of overdose, toxic symptoms can persist for 1 to 8 days owing to the prolonged elimination.

5.5 Routes of administration

Three principal routes are used clinically and in research: oral (20-microgram tablets, the most common route for the registered human therapeutic use, administered twice daily), inhalational (metered-dose inhaler or dry powder inhaler, used in some European jurisdictions), and oral solution (the veterinary Ventipulmin formulation, 72.5 micrograms per milliliter). Intravenous administration has been used in research settings but is not a registered route. Subcutaneous administration has been used in animal research.

5.6 Special populations

Pharmacokinetic data in renal impairment are limited; given the predominant renal elimination, reduced clearance and prolonged half-life should be anticipated in significant renal impairment, and dose adjustment is recommended. Hepatic impairment has minimal expected impact given the low hepatic extraction ratio. Pediatric pharmacokinetics have been characterized in the context of the bron-

chodilator indication, with weight-adjusted dosing (0.8 to 1.2 micrograms per kilogram per day in divided doses). Geriatric-specific pharmacokinetic data are limited; the prolonged half-life and the sensitivity of elderly patients to beta-adrenergic cardiovascular effects warrant conservative dosing. Pregnancy data in humans are limited; the compound is classified in pregnancy risk category C or equivalent in most jurisdictions. Use in pregnancy is generally restricted to situations where the therapeutic benefit clearly outweighs the risk.

6. Preclinical Pharmacology

6.1 Skeletal muscle anabolic effects

The anabolic effects of clenbuterol on skeletal muscle constitute the most extensively characterized preclinical pharmacology of the compound outside the bronchodilator indication. The foundational animal studies from the 1980s and 1990s established that chronic oral clenbuterol administration produces dose-dependent increases in skeletal muscle mass across species (rat, mouse, cattle, sheep, pig, horse, rabbit) and across age groups [8, 9, 20, 22].

Carter and Lynch (1994) quantified the age-dependent response in Fischer 344 rats: clenbuterol administered at 1 mg/kg/day in drinking water for 14 days increased skeletal muscle weight by 22 to 39 percent in 3-month-old rats, 19 to 35 percent in 12-month-old rats, and 22 to 25 percent in 23-month-old animals [22]. The magnitude of hypertrophy was consistently greater in fast-twitch (type IIb) fibers than in slow-twitch (type I) fibers, producing a shift in muscle fiber-type composition toward the fast-glycolytic phenotype [8, 20]. The Yimlamai et al. (2005) study demonstrated that clenbuterol at a non-myotoxic dose (approximately 0.2 mg/kg/day in rats) produced significant plantaris muscle hypertrophy with increased myofibrillar protein content and without histological evidence of muscle fiber damage [34].

The molecular mechanism involves coordinated upregulation of protein synthesis (through mTOR/S6K1 activation) and downregulation of protein degradation (through suppression of the ubiquitin-proteasome pathway, specifically the E3 ligases atrogin-1 and MuRF1, and through calpain inhibition) [25, 26]. The Kline et al. (2007) study demonstrated that the mTOR inhibitor rapamycin abolished the muscle-growth response to clenbuterol, confirming the obligatory role of mTOR signaling in the anabolic mechanism [25].

6.2 Adipose tissue lipolysis and thermogenesis

Clenbuterol activates lipolysis in white adipose tissue through beta-2 receptor-mediated activation of hormone-sensitive lipase. In animal models, chronic clenbuterol administration reduces total body fat by 10 to 25 percent depending on

dose, duration, and species [8]. The Jessen et al. (2020) human study confirmed increased energy expenditure (approximately 21 percent above baseline) and fat oxidation (approximately 20 percent above baseline) in healthy young men during a two-week clenbuterol treatment course at 40 micrograms twice daily [10]. Rothwell and Stock (1987) demonstrated that clenbuterol increased thermogenesis in both normal and protein-deficient rats through a mechanism involving upregulation of uncoupling protein expression in brown adipose tissue [35]. The lipolytic and thermogenic effects are subject to desensitization with chronic exposure, as adipocyte beta-2 receptor downregulation attenuates the response over approximately 2 to 4 weeks.

6.3 Cardiac effects: therapeutic and toxic

The cardiac pharmacology of clenbuterol presents a dual profile. At lower concentrations, beta-2 receptor activation in cardiomyocytes produces anti-apoptotic signaling through the PKA and ERK1/2 pathways, promoting cell survival and, in some models, stimulating physiological hypertrophy [31]. This cardioprotective profile was the rationale for the Harefield LVAD-bridge-to-recovery studies.

At higher doses, however, clenbuterol produces dose-dependent myocardial necrosis. Burniston et al. (2002) demonstrated that rats treated with clenbuterol at anabolic-range doses (5 mg/kg subcutaneous) developed subendocardial necrosis in the left ventricle, with the necrosis pattern peaking at 2.4 mm from the cardiac apex and being non-uniform across the myocardium [18]. The necrosis was significantly attenuated by pretreatment with the beta-blocker propranolol, confirming beta-adrenoceptor-mediated toxicity. Duncan et al. (2000) reported both myocardial and soleus muscle necrosis following chronic clenbuterol administration in rats, accompanied by impaired exercise performance [36]. The dose threshold at which therapeutic cardioprotection transitions to toxic necrosis is not precisely defined and is a critical gap in the translational pharmacology.

6.4 Neuromuscular disease models

In animal models of motor neuron disease and muscular dystrophy, clenbuterol has demonstrated efficacy through the combination of direct muscle anabolic activity and, in the case of spinal muscular atrophy, upregulation of SMN2 gene expression through beta-adrenergic signaling. Zeman et al. (2004) demonstrated that clenbuterol retarded loss of motor function in wobbler mice (a model of motor neuron

degeneration), with improved grip strength and delayed disease progression [37]. In mdx mice (a model of Duchenne muscular dystrophy), clenbuterol increased muscle mass and improved contractile function, although long-term treatment also increased susceptibility to contraction-induced damage [38]. Milioto et al. (2017) showed that beta-agonist stimulation improved the motor phenotype and increased SMN2 expression in SBMA patient-derived myotubes, providing a molecular rationale for the neuromuscular clinical trials [13].

6.5 Alpha-synuclein modulation

Mittal et al. (2017) reported that clenbuterol reduced alpha-synuclein (SNCA) gene transcription in cell culture and in mouse brain through beta-2 adrenoceptor-dependent modulation of SNCA gene promoter histone acetylation, and that beta-2 agonist use was associated with reduced risk of Parkinson's disease in a Norwegian epidemiological cohort [39]. However, Bhatt et al. (2022) demonstrated that while clenbuterol transiently decreased alpha-synuclein mRNA levels in rodent brain, no sustained reduction in alpha-synuclein protein was achieved, tempering the therapeutic relevance for Parkinson's disease [40].

7. Clinical Evidence Base

7.1 Bronchospastic airway disease

The registered indication is reversible airway obstruction in asthma and chronic obstructive pulmonary disease. Clinical trials in the 1970s and 1980s established clenbuterol at 20 micrograms twice daily as an effective bronchodilator with a duration of action of 10 to 14 hours, substantially longer than salbutamol (4 to 6 hours) [1, 41]. A double-blind crossover comparison of oral clenbuterol (20 micrograms twice daily) versus oral salbutamol (4 mg three times daily) in asthmatic outpatients demonstrated comparable bronchodilatory efficacy (FEV1 improvement), onset of action (approximately 15 minutes), and duration of effect, with a modestly lower frequency of tremor for clenbuterol at these doses [41]. Inhaled clenbuterol (20 to 40 micrograms by metered-dose inhaler) produced bronchodilation of comparable magnitude to inhaled salbutamol (200 micrograms) with modestly longer duration [42].

The compound is considered a second-line or alternative bronchodilator in jurisdictions where it is registered and is not a first-line agent in current asthma management guidelines, which favor inhaled corticosteroids with short-acting or long-acting inhaled beta-2 agonists. The narrow therapeutic index relative to salbutamol and the availability of superior alternatives are the principal reasons clenbuterol was never submitted for registration in the United States.

7.2 Spinal and bulbar muscular atrophy

Querin et al. (2013) conducted a one-year open-label pilot trial of clenbuterol at 40 micrograms daily in 20 patients with genetically confirmed spinal and bulbar muscular atrophy (Kennedy disease) [11]. The primary endpoint was the 6-minute walk test distance at 12 months. Results showed improvement in motor function measures consistent with beta-adrenoceptor-mediated muscle anabolic activity, with no relevant adverse events reported during the 12-month treatment period. The trial was a single-arm open-label design without a placebo comparator; the results are therefore hypothesis-generating and have informed the design of subsequent controlled trials.

7.3 Amyotrophic lateral sclerosis

A pilot trial by Meijer et al. (2006) evaluated clenbuterol in 16 patients with amyotrophic lateral sclerosis over 6 months at escalating doses of 40 to 80 micrograms daily [43]. The trial reported adequate safety and tolerability but was underpowered for efficacy endpoints. A subsequent larger open-label trial (NCT04245709) by Meijer et al. (2023) studied clenbuterol in ALS patients starting at 40 micrograms daily and escalating to 80 micrograms twice daily [12]. This trial reported that clenbuterol treatment was safe and was associated with slowed functional decline compared to historical controls. The evidence base in ALS remains preliminary, consisting of open-label and historical-control comparisons without randomized placebo-controlled confirmation.

7.4 Cardiac bridge-to-recovery

The Harefield Hospital group, led by Yacoub and colleagues, investigated clenbuterol as part of a multi-drug pharmacological protocol in patients with end-stage heart failure supported by left ventricular assist devices (LVADs). The rationale was that beta-2 agonist-mediated cardiac myocyte hypertrophy, combined with mechanical unloading by the LVAD, would promote reverse myocardial remodeling sufficient to permit device explantation. The Birks et al. (2006) study in The New England Journal of Medicine reported that 11 of 15 patients (73 percent) treated with the combined protocol (LVAD support plus clenbuterol, lisinopril, carvedilol, spironolactone, losartan) demonstrated sufficient myocardial recovery to undergo LVAD explantation, with 4-year freedom from recurrent heart failure of 89 percent [14]. Clenbuterol doses in this protocol were escalated from 40 micrograms three times daily to 720 micrograms three times daily over the course of LVAD support. The contribution of clenbuterol specifically (versus the combined protocol) to recovery has not been established in a controlled factorial design.

7.5 Spinal muscular atrophy

Clinical trials specifically evaluating clenbuterol in spinal muscular atrophy (SMA) are in progress (NCT03860870). The preclinical rationale is based on the demonstration that beta-2 agonist stimulation increases expression of the survival motor neuron 2 (SMN2) gene, the therapeutic target in SMA, through cAMP-responsive element binding protein (CREB)-mediated transcriptional activation [13]. This mecha-

nism is complementary to the antisense oligonucleotide (nusinersen) and gene therapy (onasemnogene abeparvovec) approaches that constitute the current standard of care for SMA.

7.6 Body composition in healthy subjects

The Jessen et al. (2020) randomized controlled study in healthy young men is the most rigorous published human evidence for clenbuterol's body-composition effects in a non-disease population [10]. Clenbuterol at 40 micrograms twice daily for 14 days produced significant increases in energy expenditure and fat oxidation, and mTOR pathway activation (S6 phosphorylation) was confirmed in skeletal muscle biopsies. A 2025 controlled study in horses (Kamalakkannan et al.) demonstrated that clenbuterol treatment for 14 days produced approximately 8 percent increase in lean mass and greater than 15 percent decrease in fat mass, accompanied by significant muscle protein accretion measured by stable isotope tracer methodology, but also demonstrated desensitization of skeletal muscle beta-2 adrenergic signaling and impairment of cardiorespiratory fitness [30]. Extrapolation of animal body-composition data to human performance contexts is scientifically imprecise and not supported by the controlled clinical evidence base.

7.7 Muscle-wasting conditions

Several additional clinical studies have evaluated clenbuterol in muscle-wasting contexts. Maltin et al. (1993) conducted a study of clenbuterol in patients with muscle atrophy following orthopedic injury, reporting increased relative muscle strength in the clenbuterol group [44]. The Abresch and Kissel groups evaluated the related beta-2 agonist albuterol (salbutamol) in facioscapulohumeral dystrophy and SMA, with results informing the clenbuterol research program [45, 46]. The evidence base for clenbuterol in muscle-wasting conditions remains in the pilot-study and open-label phase; no large randomized placebo-controlled registration trials have been completed.

8. Sourcing and Quality Verification

Pharmaceutical-grade clenbuterol hydrochloride (Spiropent brand or licensed generic) is the highest quality source for research applications where regulatory equivalence to clinical material is operationally important. The pharmaceutical-grade material is supplied as 20-microgram or 40-microgram oral tablets in the marketed formulations. Pharmaceutical sourcing is feasible in jurisdictions where the compound is registered for human use (Germany, Italy, Spain, Mexico, Brazil, and others). The veterinary Ventipulmin Syrup formulation (72.5 micrograms per milliliter) is available in the United States through licensed veterinary suppliers.

Research-grade clenbuterol hydrochloride is supplied by multiple chemical and pharmaceutical research suppliers (Sigma-Aldrich, Cayman Chemical, Tocris, MedChemExpress, Santa Cruz Biotechnology, TCI America, and others) at greater than 98 percent purity by HPLC. Supply is typically in milligram to gram quantities as the hydrochloride salt. Pricing is moderate, in the range of \$30 to \$150 per gram of research-grade material at the time of monograph preparation.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity, ideally greater than 98 percent
- Mass spectrometry confirmation of molecular weight (278.09 for the protonated free base $[M+H]^+$)
- Nuclear magnetic resonance spectroscopy (1H and ^{13}C) for structural confirmation
- Chiral HPLC or polarimetry if enantiopure material is required for mechanism studies
- Karl Fischer or loss-on-drying analysis for residual water content
- Residual solvent analysis by gas chromatography (common synthesis solvents: methanol, ethanol, dichloromethane, ethyl acetate)

Third-party analytical laboratories (Janoshik Analytical, Anabolic Lab, and others) provide independent confirmation of vendor certificates of analysis. The research-grade clenbuterol market is well established but intersects with the performance-

enhancement supplement market, which introduces a non-trivial risk of mislabeled, underdosed, or contaminated material from non-pharmaceutical sources. Certificate of analysis verification against an independent analytical standard is recommended for any investigation where dose-response precision is important.

9. Reconstitution and Handling

Clenbuterol hydrochloride is freely soluble in water at room temperature (solubility approximately 50 mg/mL). For research applications, the compound is typically supplied as a crystalline powder and is reconstituted as needed. Stock solutions for *in vitro* studies are commonly prepared at 10 mM in dimethyl sulfoxide (DMSO) or at 1 to 10 mg/mL in sterile water, phosphate-buffered saline, or normal saline.

For *in vivo* animal research, clenbuterol is commonly administered in drinking water (at concentrations of 10 to 30 mg/L, producing approximate daily doses of 1 to 3 mg/kg in rodents) or by subcutaneous injection of freshly prepared aqueous solutions. For clinical research formulations, oral tablets (20 microgram) or syrup preparations are the standard vehicles.

Storage of the solid should be at room temperature (15 to 30 degrees Celsius) or at refrigerated conditions (2 to 8 degrees Celsius) in a desiccated, light-protected environment. The compound is stable under these conditions for at least 24 months as the solid salt. Aqueous solutions should be stored at 2 to 8 degrees Celsius and used within 14 to 30 days of preparation when reconstituted with bacteriostatic water, or within 24 hours when reconstituted with sterile water for injection. DMSO stock solutions can be stored at negative 20 degrees Celsius for up to 6 months.

Aliquoting of stock solutions is recommended to minimize repeated freeze-thaw cycles. The compound is not classified as a controlled substance in most jurisdictions but is a prohibited substance under anti-doping regulations; investigators in sporting contexts should maintain appropriate chain-of-custody documentation.

10. Stack Interactions and Combinations

Clenbuterol interacts with several drug classes through its beta-adrenergic pharmacology and its renal elimination pathway. Investigators conducting research with clenbuterol, particularly in chronic dosing or combination protocols, should consider:

Beta-blockers (beta-1 selective and non-selective): Non-selective beta-blockers (propranolol, nadolol) antagonize the bronchodilator and anabolic effects of clenbuterol through competitive inhibition at the beta-2 receptor. Beta-1-selective blockers (metoprolol, atenolol, bisoprolol) have less impact on beta-2-mediated effects but may attenuate the cardiac stimulatory effects. The combination has been deliberately employed in research (propranolol to block clenbuterol-induced myocardial necrosis) and in the Harefield LVAD protocol (carvedilol co-administered with clenbuterol) [14, 18].

Other beta-2 agonists: Concurrent use with salbutamol, formoterol, salmeterol, or other beta-2 agonists produces additive beta-adrenergic stimulation and increased risk of tachycardia, tremor, and hypokalemia. The combination is pharmacologically redundant for most indications and is not recommended.

Corticosteroids: Systemic corticosteroids and beta-2 agonists both produce hypokalemia through different mechanisms (corticosteroid-mediated renal potassium wasting; beta-2-mediated cellular potassium uptake). Concurrent use increases the risk of clinically significant hypokalemia.

Cardiac glycosides (digoxin): Clenbuterol-induced hypokalemia increases the risk of digitalis toxicity in patients receiving concurrent digoxin.

QT-prolonging agents: Clenbuterol-induced hypokalemia and possible direct QT-prolonging effects increase the risk of torsade de pointes when combined with other QT-prolonging agents (fluoroquinolones, macrolide antibiotics, antiarrhythmics, antipsychotics, methadone).

Sympathomimetic amines: Concurrent use with other sympathomimetics (ephedrine, pseudoephedrine, caffeine at high doses, amphetamines) produces additive adrenergic stimulation with increased cardiovascular risk. The combination of clenbuterol with caffeine or other methylxanthines (theophylline) also produces additive sympathomimetic effects.

Monoamine oxidase inhibitors: The combination is contraindicated due to the risk of hypertensive crisis from potentiated sympathomimetic activity.

Potassium-depleting diuretics: Concurrent use with thiazide or loop diuretics increases the risk of hypokalemia.

Insulin and oral hypoglycemic agents: Clenbuterol produces acute hyperglycemia through beta-2-mediated hepatic glycogenolysis; chronic administration has been associated with variable glycemic effects. The interaction is relevant in diabetic research participants.

Anabolic-androgenic steroids: The combination of clenbuterol with testosterone, nandrolone, or other anabolic steroids is commonly reported in bodybuilding contexts. Preclinical data suggest that the anabolic mechanisms are at least partially independent (steroid-mediated nuclear receptor signaling versus beta-2 adrenoceptor-mediated PKA/mTOR signaling), and additive lean mass accretion has been demonstrated in animal models. The cardiovascular risk of the combination exceeds that of either agent alone.

Thyroid hormones: The combination of clenbuterol with exogenous triiodothyronine (T3) is commonly reported for synergistic fat loss. The combination produces additive thermogenic and metabolic effects but also additive cardiac stimulation, with substantially elevated cardiovascular risk.

11. Adverse Events and Safety

11.1 Common adverse events at therapeutic doses

The principal adverse events at the registered bronchodilator dose range (20 to 40 micrograms twice daily) are:

- Tremor (15 to 20 percent; fine tremor of the extremities, reflecting direct beta-2 receptor stimulation in skeletal muscle)
- Tachycardia (5 to 10 percent; reflecting both beta-1 and beta-2 receptor stimulation in the heart)
- Headache (5 to 8 percent)
- Nervousness and insomnia (3 to 5 percent)
- Muscle cramps (2 to 5 percent; mechanism multifactorial, possibly related to electrolyte shifts)
- Palpitations (2 to 4 percent)
- Hypokalemia (dose-dependent; reflects beta-2-mediated cellular potassium uptake)

Long-term clinical use at therapeutic doses (20 to 60 micrograms daily for up to 1 year) has been reported without major adverse events beyond tremor and occasional mild tachycardia [1].

11.2 Adverse events at supratherapeutic doses

At the doses commonly used in performance-enhancement and body-composition contexts (60 to 200 micrograms daily or higher, often escalating over multiple weeks), the adverse-event profile is substantially more severe:

- Significant tachycardia (resting heart rate 100 to 140 beats per minute)
- Hypokalemia (serum potassium less than 3.0 mmol/L in severe cases)
- Incapacitating tremor
- Labile blood pressure (hypertension followed by hypotension)
- QT interval prolongation

- Chest pain and myocardial ischemia
- Nausea and vomiting
- Hyperglycemia
- Agitation, anxiety, and insomnia
- Rhabdomyolysis (rare)

In the Spiller et al. (2013) poison center series of 63 clenbuterol exposures, tachycardia was documented in 82 percent, tremor in 24 percent, hypokalemia in 14 percent, and agitation in 14 percent of intentional exposures. Over 80 percent of patients required emergency department evaluation [16].

11.3 Cardiac toxicity

Cardiac toxicity is the most serious safety concern with clenbuterol. Case reports in the clinical toxicology literature document hospitalization for tachyarrhythmia (supraventricular tachycardia, atrial fibrillation, ventricular tachycardia), myocardial ischemia, myocarditis, and at least one case of cardiac arrest in a young adult following suprathreshold clenbuterol use [15, 16, 17, 47]. Goldstein et al. (1998) published one of the earliest case reports of myocardial infarction with normal coronary arteries in a clenbuterol user [15]. Kierzkowska et al. (2005) reported myocardial infarction in a 17-year-old bodybuilder [48]. A systematic review by Daubert et al. (2007) reported that 84 percent of patients with clenbuterol exposure presenting to emergency departments required hospitalization [17].

Animal evidence confirms dose-dependent myocardial necrosis. The Burniston et al. (2002) study in Wistar rats demonstrated left ventricular subendocardial necrosis following clenbuterol at anabolic-range doses, with the necrosis pattern being non-uniform, most abundant in the left ventricular subendocardium, and significantly reduced by propranolol pretreatment [18]. The mechanism appears to involve demand ischemia (increased myocardial oxygen demand from beta-1-mediated chronotropy and inotropy exceeding coronary supply) and possibly direct beta-2-mediated calcium overload in cardiomyocytes.

No minimum dose for cardiac toxicity has been definitively established in humans. Case reports of cardiac effects at doses as low as 20 to 80 micrograms daily have been published, although the majority of serious cardiac events occur at

suprathreshold doses [48]. The narrow and poorly defined margin between the anabolic dose range and the cardiac toxic dose range is a fundamental limitation for all non-bronchodilator applications of clenbuterol.

11.4 Desensitization and tolerance

Progressive tolerance to the bronchodilator, anabolic, and thermogenic effects of clenbuterol develops with chronic administration through beta-2 receptor down-regulation (Section 4.3). The desensitization has both safety and efficacy implications: it attenuates the therapeutic bronchodilator effect, it limits the duration of anabolic efficacy, and it may paradoxically increase the risk of cardiovascular adverse events if doses are escalated to overcome tolerance.

11.5 Food safety

Clenbuterol residues in meat from illegally treated livestock constitute a public health hazard. The Spanish incident of 1990 (over 100 individuals acutely poisoned from contaminated beef liver) and subsequent incidents in China, Mexico, and other countries have established the food-safety risk [23]. Symptoms of clenbuterol food poisoning include tremor, tachycardia, headache, nausea, and in severe cases, hypokalemia and cardiac arrhythmia.

12. Comparative Assessment

This section presents a structured comparative assessment of five alternative beta-2 adrenergic receptor agonists against clenbuterol, evaluated against five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five comparators were selected to span the beta-2 agonist class across different pharmacokinetic profiles and clinical applications: two short-acting agents (salbutamol, terbutaline), two long-acting agents (formoterol, salmeterol), and one experimental anabolic beta-2 agonist (BRL-47672).

12.1 Salbutamol (Albuterol)

Mechanism: Selective beta-2 adrenergic receptor agonist. Short-acting, with an elimination half-life of 4 to 6 hours.

Development trajectory: Developed by Allen and Hanburys (now GlaxoSmithKline) in the 1960s. Approved worldwide for bronchospastic airway disease. The most widely prescribed short-acting beta-2 agonist globally and the reference standard of the class.

Novelty: Low. Salbutamol is the prototypical selective beta-2 agonist and the historical reference compound.

Effect size: For bronchodilation, salbutamol is the benchmark. For anabolic and repartitioning effects, salbutamol has been studied (particularly oral formulation at 4 mg three times daily) and produces modest muscle anabolic effects in humans, but substantially less than clenbuterol at equi-effective bronchodilator doses, attributable to the shorter half-life and lower tissue accumulation [49]. Oral salbutamol has been investigated in neuromuscular disease (SMA) and has shown SMN2 upregulation similar to clenbuterol [46].

Promising potential: High for bronchodilation (the global standard of care). Moderate for anabolic applications (limited by short half-life and modest tissue accumulation).

Side-effect profile: Tremor, tachycardia, and hypokalemia, qualitatively similar to clenbuterol but generally less severe owing to the shorter duration of action. Cardiac toxicity at suprathreshold doses is documented but is less prominent in the clinical toxicology literature than with clenbuterol. The safety margin is wider.

Overall validation: Very high. Salbutamol has a global safety database spanning decades and is one of the most extensively validated pharmaceutical compounds in clinical medicine.

Comparison to clenbuterol: Salbutamol has a vastly more extensive safety database and a more favorable regulatory position (FDA-approved for human use). Clenbuterol has the advantage of a substantially longer half-life, greater anabolic potency at clinically achievable doses, and superior repartitioning efficacy in animal and human studies. For bronchodilator applications, salbutamol is preferred. For anabolic and neuromuscular research applications, clenbuterol has a pharmacokinetic advantage.

12.2 Formoterol

Mechanism: Selective beta-2 adrenergic receptor full agonist. Long-acting, with a duration of bronchodilator effect of approximately 12 hours and an elimination half-life of approximately 10 hours.

Development trajectory: Developed by Yamanouchi (now Astellas) and Novartis. Approved worldwide for asthma and COPD as an inhaled long-acting beta-2 agonist (LABA), typically in fixed-dose combinations with inhaled corticosteroids.

Novelty: Moderate. Formoterol introduced the concept of a rapid-onset full-agonist LABA and remains a cornerstone of current inhaled therapy.

Effect size: For bronchodilation, formoterol has a rapid onset (1 to 3 minutes) combined with a 12-hour duration, a profile superior to both salbutamol and clenbuterol for inhaled use. For anabolic effects, formoterol has been studied in pre-clinical cachexia models and demonstrates muscle-sparing activity attributed to the same beta-2-mediated anti-proteolytic mechanism as clenbuterol [50]. Human anabolic data are limited.

Promising potential: High for bronchodilation (a current standard-of-care LABA). Moderate for anabolic applications (preclinical evidence in cachexia, limited clinical data).

Side-effect profile: Tremor, tachycardia, and hypokalemia at high doses. The inhaled route of administration minimizes systemic exposure and substantially reduces the cardiovascular adverse-event burden relative to oral clenbuterol. Beta-2/beta-1 selectivity is approximately 120:1, substantially superior to clenbuterol.

Overall validation: Very high for inhaled bronchodilator use. Low for systemic anabolic applications.

Comparison to clenbuterol: Formoterol is a superior bronchodilator for inhaled use due to its rapid onset and 12-hour duration. Clenbuterol has the advantage for systemic anabolic applications owing to its longer oral half-life and greater tissue accumulation. The two compounds are not direct competitors in clinical practice.

12.3 Salmeterol

Mechanism: Selective beta-2 adrenergic receptor partial agonist. Long-acting, with a duration of bronchodilator effect of approximately 12 hours. The long duration is attributed to the exosite binding model, in which the lipophilic side chain anchors in a hydrophobic groove adjacent to the orthosteric binding site.

Development trajectory: Developed by GlaxoSmithKline. Approved worldwide for asthma and COPD as an inhaled LABA. Available as Serevent and in fixed-dose combination with fluticasone (Advair/Seretide).

Novelty: Low. Salmeterol is a well-established LABA now partially superseded by formoterol and ultra-long-acting agents.

Effect size: For bronchodilation, comparable to formoterol in duration but with a slower onset (15 to 30 minutes). For anabolic effects, salmeterol has minimal characterization; its partial agonist profile and low systemic bioavailability from inhaled delivery make it a poor candidate for anabolic applications.

Promising potential: Moderate for inhaled bronchodilator use (well established but increasingly replaced by formoterol-containing combinations). Not applicable for anabolic applications.

Side-effect profile: Favorable at registered inhaled doses. The partial agonist profile limits maximal cardiovascular stimulation. Beta-2/beta-1 selectivity is approximately 50,000:1, the highest in the marketed beta-2 agonist class.

Overall validation: High for inhaled bronchodilator use. Not evaluated for anabolic applications.

Comparison to clenbuterol: Salmeterol is irrelevant as a comparator for anabolic or repartitioning research. Its inclusion illustrates the wide pharmacological separation between inhaled LABAs optimized for airway selectivity and oral beta-2 agonists with systemic tissue effects.

12.4 Terbutaline

Mechanism: Selective beta-2 adrenergic receptor agonist. Short-acting, with an elimination half-life of approximately 3 to 4 hours.

Development trajectory: Developed by Draco (now AstraZeneca). Approved for bronchospasm (oral, inhaled, and subcutaneous formulations) and for acute tocolysis (subcutaneous, to arrest preterm labor).

Novelty: Low. Terbutaline is one of the earliest selective beta-2 agonists and a long-established clinical agent.

Effect size: For bronchodilation, comparable to salbutamol. For anabolic effects, terbutaline has been studied in animal models and produces measurable skeletal muscle hypertrophy, but with a magnitude less than clenbuterol at comparable doses, attributable to the shorter half-life and lower tissue accumulation [51]. The tocolytic application is the principal clinical use that differentiates terbutaline from salbutamol.

Promising potential: Moderate for bronchodilation and tocolysis. Low for anabolic applications.

Side-effect profile: Tremor, tachycardia, hypokalemia; similar to salbutamol. The subcutaneous formulation has been associated with maternal cardiac adverse events in the tocolytic context with prolonged use.

Overall validation: High for bronchodilator and tocolytic use. Low for anabolic applications.

Comparison to clenbuterol: Terbutaline has the regulatory advantage of FDA approval (including subcutaneous formulation) and an established safety database. Clenbuterol has the pharmacokinetic advantage of a 10-fold longer half-life and substantially greater anabolic potency.

12.5 BRL-47672

Mechanism: Selective beta-2 adrenergic receptor agonist designed specifically for skeletal muscle anabolic activity with reduced cardiovascular stimulation. The compound was developed at SmithKline Beecham (now GlaxoSmithKline) as a purpose-built "anabolic beta-agonist" intended to separate the muscle-growth and lipolytic effects from the cardiac effects of the class [52].

Development trajectory: Preclinical only. BRL-47672 was characterized in the late 1990s in rodent models and demonstrated potent skeletal muscle hypertrophy with a reported wider margin between the anabolic and cardiac-toxic dose ranges than clenbuterol. The compound was not advanced to clinical development and remains a research tool.

Novelty: Moderate to high. The design concept of an anabolic-selective beta-2 agonist is pharmacologically novel and directly addresses the principal limitation of clenbuterol (cardiac toxicity at anabolic doses).

Effect size: In preclinical models, BRL-47672 produced anabolic effects on skeletal muscle comparable to or exceeding clenbuterol with a larger safety margin for cardiac effects.

Promising potential: Low as a clinical candidate (never advanced to human trials). High as a pharmacological concept that informs the design of next-generation tissue-selective beta-2 agonists.

Side-effect profile: Preclinical data suggest a wider therapeutic index than clenbuterol for anabolic applications. No human safety data exist.

Overall validation: Low. The compound is a research tool with no clinical validation.

Comparison to clenbuterol: BRL-47672 represents the pharmacological aspiration for the beta-2 agonist anabolic class: tissue-selective muscle growth with minimal cardiac liability. Clenbuterol has the advantages of extensive characterization, clinical safety data at bronchodilator doses, and operational availability. BRL-47672 has the conceptual advantage of designed tissue selectivity but no clinical evidence.

12.6 Comparator summary

The five compounds span the beta-2 adrenergic agonist pharmacological space from short-acting bronchodilators to experimental anabolic agents. **Salbutamol** is the global reference short-acting beta-2 agonist with the widest therapeutic index and the broadest safety database, with established use in SMA research but modest anabolic potential. **Formoterol** is the preferred long-acting beta-2 agonist for inhaled bronchodilation with emerging preclinical interest in cachexia. **Salmeterol** is a partial agonist LABA with extreme beta-2 selectivity, irrelevant for anabolic applications. **Terbutaline** is a short-acting agent with tocolytic and bronchodilator indications and modest anabolic potential. **BRL-47672** is an experimental anabolic-selective beta-2 agonist that embodies the concept of separating muscle growth from cardiac toxicity.

Clenbuterol occupies a unique position in this landscape as the most extensively characterized oral beta-2 agonist for skeletal muscle anabolic and body-composition repartitioning applications. It is the only compound in this comparator set with: (a) a 25- to 39-hour oral half-life that supports sustained tissue exposure from once- or twice-daily dosing; (b) extensive preclinical characterization across species and age groups for muscle hypertrophy; (c) pilot clinical trial data in neuromuscular disease (SBMA, ALS); (d) clinical evidence for myocardial reverse remodeling in the LVAD bridge-to-recovery context; and (e) operational availability in multiple pharmaceutical and research-grade formulations globally.

The principal limitation of clenbuterol relative to the comparator panel is the narrow therapeutic index for anabolic applications, where the dose range that produces meaningful skeletal muscle growth overlaps with or exceeds the dose range at which cardiac toxicity has been documented. This limitation is the fundamental pharmacological challenge for all systemic beta-2 agonist anabolic strategies and is the design rationale for tissue-selective candidates such as BRL-47672. Investigators considering clenbuterol for anabolic, neuromuscular, or cardiac research should design dosing protocols with careful attention to the cardiac risk, should monitor electrocardiography and serum potassium, and should consider the desensitization kinetics that limit anabolic efficacy beyond approximately 2 to 4 weeks of continuous administration.

13. References

1. Engelhardt G. Dose-response relationship of clenbuterol (NAB 365) as a solution for inhalation. *Arzneimittelforschung*. 1976;26(7a):1404-1408.
2. Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. *J Allergy Clin Immunol*. 2006;117(1):18-24.
3. Dalglish CE, Johnson AW, Todd AR. The stereochemistry of sympathomimetic amines and beta-adrenergic receptor selectivity. In: *Advances in Drug Research*. Academic Press; 1972.
4. Kannasani RK, Peruri BG, Gilla G. Synthesis and characterization of bromoclenbuterol. *Med Chem (Los Angeles)*. 2016;6(8):397-402.
5. Boehringer Ingelheim. Aminohalogenbenzylamines. US Patent 3,536,712. Filed 1968, granted 1970.
6. Yamamoto I, Iwata K, Nakashima M. Pharmacokinetics of plasma and urine clenbuterol in man, rat, and rabbit. *J Pharmacobiodyn*. 1985;8(5):385-391.
7. World Health Organization. 874. Clenbuterol. WHO Food Additives Series 38. International Programme on Chemical Safety; 1996.
8. Ricks CA, Dalrymple RH, Baker PK, Ingle DL. Use of a beta-agonist to alter fat and muscle deposition in steers. *J Anim Sci*. 1984;59(5):1247-1255.
9. Reeds PJ, Hay SM, Dorwood PM, Palmer RM. Stimulation of muscle growth by clenbuterol: lack of effect on muscle protein biosynthesis. *Br J Nutr*. 1986;56(1):249-258.
10. Jessen S, Solheim SA, Jacobson GA, et al. Beta-2 adrenergic agonist clenbuterol increases energy expenditure and fat oxidation, and induces mTOR phosphorylation in skeletal muscle of young healthy men. *Drug Test Anal*. 2020;12(5):610-618.
11. Querin G, D'Ascenzo C, Peterle E, et al. Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. *Neurology*. 2013;80(23):2095-2098.

12. Meijer NWF, Tieleman AA, van Vught PWJ, et al. Clenbuterol treatment is safe and associated with slowed disease progression in a small open-label trial in patients with amyotrophic lateral sclerosis. *J Neurol*. 2023;270(8):3988-3995.
13. Milioto C, Malena A, Maino E, et al. Beta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes. *Sci Rep*. 2017;7:41046.
14. Birks EJ, Tansley PD, Hardy J, et al. Left ventricular assist device and drug therapy for the reversal of heart failure. *N Engl J Med*. 2006;355(18):1873-1884.
15. Goldstein DR, Dobbs T, Krull B, Plumb VJ. Clenbuterol and anabolic steroids: a previously unreported cause of myocardial infarction with normal coronary arteries. *South Med J*. 1998;91(8):780-784.
16. Spiller HA, James KJ, Scholzen S, Borys DJ. A descriptive study of adverse events from clenbuterol misuse and abuse for weight loss and bodybuilding. *Subst Abus*. 2013;34(3):306-312.
17. Daubert GP, Mabasa VH, Leung VW, Thompson C. Acute clenbuterol overdose resulting in supraventricular tachycardia and atrial fibrillation. *J Med Toxicol*. 2007;3(2):56-60.
18. Burniston JG, Tan LB, Goldspink DF. Myotoxic effects of clenbuterol in the rat heart and soleus muscle. *J Appl Physiol*. 2002;93(5):1824-1832.
19. United States Food and Drug Administration. NADA 140-973: Ventipulmin Syrup (clenbuterol hydrochloride). Boehringer Ingelheim Vetmedica, Inc. Approved 1998.
20. Maltin CA, Reeds PJ, Delday MI, Hay SM, Smith FG, Lobley GE. Inhibition and reversal of denervation-induced atrophy by the beta-agonist growth promoter clenbuterol. *Biosci Rep*. 1986;6(9):811-818.
21. Choo JJ, Horan MA, Little RA, Rothwell NJ. Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation. *Am J Physiol*. 1992;263(1 Pt 1):E50-E56.
22. Carter WJ, Lynch ME. Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats. *Metabolism*. 1994;43(9):1119-1125.

23. Pulce C, Lamaison D, Keck G, et al. Collective human food poisonings by clenbuterol residues in veal liver. *Vet Hum Toxicol*. 1991;33(5):480-481.
24. World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List 2026. WADA; 2026.
25. Kline WO, Panaro FJ, Yang H, Bodine SC. Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. *J Appl Physiol*. 2007;102(2):740-747.
26. Navegantes LC, Resano NM, Baviera AM, et al. Effect of sympathetic denervation on the rate of protein synthesis in rat skeletal muscle. *Am J Physiol Endocrinol Metab*. 2004;286(4):E642-E647.
27. Spurlock DM, McDanel TG, McIntyre LM. Changes in skeletal muscle gene expression following clenbuterol administration. *BMC Genomics*. 2006;7:320.
28. O'Donnell SR, Wanstall JC. Analysis of the beta-1 and beta-2 adrenoceptor interactions of the partial agonist, clenbuterol (NAB 365), in the rat jugular vein and atria. *Naunyn Schmiedebergs Arch Pharmacol*. 1985;328(3):263-268.
29. McGraw DW, Liggett SB. Molecular mechanisms of beta-2 adrenergic receptor function, response, and regulation. *Proc Am Thorac Soc*. 2005;2(4):292-296.
30. Kamalakkannan G, Petrilli CM, George I, et al. Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle beta-2 adrenergic signalling. *J Physiol*. 2025 (epub ahead of print).
31. Zhu WZ, Zheng M, Koch WJ, et al. Dual modulation of cell survival and cell death by beta-2 adrenergic signaling in adult mouse cardiac myocytes. *Proc Natl Acad Sci USA*. 2001;98(4):1607-1612.
32. Chen HZ, Zhu J, Wang JL, et al. Pharmacokinetics of ambroxol and clenbuterol tablets in healthy Chinese volunteers. *Int J Clin Exp Med*. 2015;8(10):18744-18750.
33. Ibid.
34. Yimlamai T, Dodd SL, Stephenson SE, et al. Anabolic effects of a non-myotoxic dose of the beta-2 adrenergic receptor agonist clenbuterol on the rat plantaris muscle. *Proc Nutr Soc*. 2005;64(suppl 1):1852.

35. Rothwell NJ, Stock MJ. Effect of a selective beta-2 adrenergic agonist (clenbuterol) on energy balance and body composition in normal and protein deficient rats. *Biosci Rep.* 1987;7(12):933-940.
36. Duncan ND, Williams DA, Lynch GS. Deleterious effects of chronic clenbuterol treatment on endurance and sprint exercise performance in rats. *Clin Sci (Lond).* 2000;98(3):339-347.
37. Zeman RJ, Peng H, Etlinger JD. Clenbuterol retards loss of motor function in motor neuron degeneration mice. *Exp Neurol.* 2004;187(2):460-467.
38. Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. *J Physiol.* 2001;535(Pt 2):591-600.
39. Mittal S, Bjornevik K, Im DS, et al. Beta2-adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson's disease. *Science.* 2017;357(6354):891-898.
40. Bhatt D, Bhatt S, Bhatt L, et al. Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein. *NPJ Parkinsons Dis.* 2022;8(1):61.
41. Warwick BT, Rees PJ. Double-blind cross-over comparison of clenbuterol and salbutamol tablets in asthmatic out-patients. *Eur J Clin Pharmacol.* 1978;14(2):159-163.
42. Fuso L, Basso S, Contu P, et al. A comparison between inhaled clenbuterol and salbutamol in chronic bronchitis with reversible airway obstruction. *Int J Clin Pharmacol Ther Toxicol.* 1982;20(9):423-426.
43. Meijer JM, Graus YM, Veldink JH, van den Berg LH. A pilot trial with clenbuterol in amyotrophic lateral sclerosis. *Amyotroph Lateral Scler.* 2006;7(4):246-248.
44. Maltin CA, Delday MI, Watson JS, et al. Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. *Clin Sci (Lond).* 1993;84(6):651-654.
45. Kissel JT, McDermott MP, Mendell JR, et al. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. *Neurology.* 2001;57(8):1434-1440.

46. Tiziano FD, Lomastro R, Pinto AM, et al. Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. *J Med Genet*. 2010;47(12):856-858.
47. Tofighi B, Bilfinger TV, Bhargava HK. Clenbuterol-induced myocarditis: a case report. *Eur J Case Rep Intern Med*. 2020;7(9):001662.
48. Kierzkowska B, Stanczyk J, Kasprzak JD. Myocardial infarction in a 17-year-old body builder using clenbuterol. *Circ J*. 2005;69(9):1144-1146.
49. Carter WJ, Lynch ME. Comparison of the effects of salbutamol and clenbuterol on skeletal muscle mass and carcass composition in senescent rats. *Metabolism*. 1994;43(9):1119-1125.
50. Busquets S, Figueras MT, Fuster G, et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. *Cancer Res*. 2004;64(18):6725-6731.
51. Ryall JG, Sillence MN, Lynch GS. Systemic administration of beta-2 adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. *Br J Pharmacol*. 2006;147(6):587-595.
52. Ryall JG, Lynch GS. The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting. *Pharmacol Ther*. 2008;120(3):219-232.

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Clenbuterol is not approved by the United States Food and Drug Administration for human use. The compound is classified as a prohibited substance by the World Anti-Doping Agency. Its use as a growth-promoting agent in food-producing animals is prohibited in the European Union, the United States, and China. Investigators should consult their local regulatory authority and institutional review requirements before any research application. The cardiac toxicity profile at supratherapeutic doses constitutes a material safety concern that must be addressed in any research protocol involving chronic or high-dose administration.